Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians.
about
Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?Phagocyte NADPH oxidase, chronic granulomatous disease and mycobacterial infections.Reactivation of Tuberculosis in Three Cases of Psoriasis after Initiation of Anti-TNF Therapy.Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease.General health maintenance in IBD.Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.Biologics in oral medicine: principles of use and practical considerations.Biologics in dermatology: adverse effects.Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.Multidrug resistant miliary tuberculosis during infliximab therapy despite tuberculosis screening.The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy: case report.Psoriasis: an evidence-based update. Report of the 9th evidenced based update meeting, 12 May 2011, Loughborough, UK.Tuberculosis risk and biological therapy for psoriasis.
P2860
Q33939033-DDACF4C9-BE7B-4D79-97FB-16A4DB9CF122Q34074149-DFCAB743-7216-4203-9126-2137E023356DQ34423996-ACF78CC4-0DE3-4541-B5D7-D719381C42BDQ35903142-08C66B40-9262-48EA-8C5E-3FE64AA8ACA4Q36176854-4367E7E4-471F-4381-A006-7FBA23532B77Q37223472-01162244-69F8-4A1A-8588-6213BB3E9C56Q37547079-C1DD0F20-88AF-47E3-9D67-3AE537D5E79FQ37810305-9E25ECCA-E400-499B-8DB0-0CBB60FD645BQ37980484-CE32C2D3-CF3E-4457-B643-10431DBBD9E3Q37993932-CAAAA0E4-560F-4541-B189-A6511BBA7708Q41120913-215B3332-7640-42EC-BE41-B87E0A546C87Q41688405-89E07251-6ECB-4292-9EB5-0ECEDE986F15Q45921031-9B9CCF68-2C34-4B27-AF6B-16D91A5DBFDFQ46758133-9B524BA7-3DA4-4C41-B7E9-18657AE9AAA6Q48786883-235CA650-E0D9-4674-B5A4-79BF248B6A30Q50973080-E201860D-ADAE-47B5-A104-C91438B93FB1Q51625861-727D863D-F833-409B-A74E-57CB5504E467
P2860
Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tuberculosis and tumour necros ...... tic guidelines for clinicians.
@en
Tuberculosis and tumour necros ...... tic guidelines for clinicians.
@nl
type
label
Tuberculosis and tumour necros ...... tic guidelines for clinicians.
@en
Tuberculosis and tumour necros ...... tic guidelines for clinicians.
@nl
prefLabel
Tuberculosis and tumour necros ...... tic guidelines for clinicians.
@en
Tuberculosis and tumour necros ...... tic guidelines for clinicians.
@nl
P2093
P2860
P1476
Tuberculosis and tumour necros ...... tic guidelines for clinicians.
@en
P2093
P2860
P356
10.1111/J.1365-2133.2008.08891.X
P407
P577
2008-10-22T00:00:00Z